Corbus Pharmaceuticals Holdings Inc. Daily Stock Analysis

Daily Stock Analysis, CRBP, Corbus Pharmaceuticals Holdings Inc, priceseries

Corbus Pharmaceuticals Holdings Inc. Daily Stock Analysis
Stock Information
Open
0.34
Close
0.32
High
0.34
Low
0.31
Previous Close
0.34
Daily Price Gain
-0.02
YTD High
0.67
YTD High Date
Jan 3, 2022
YTD Low
0.30
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.35
YTD Gain
-52.33%
52 Week High
2.46
52 Week High Date
Mar 15, 2021
52 Week Low
0.30
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-1.54
52 Week Gain
-82.93%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 10. 2017
7.10
Mar 14. 2017
8.90
21 Trading Days
25.36%
Link
LONG
Aug 23. 2017
6.15
Sep 7. 2017
7.10
10 Trading Days
15.43%
Link
LONG
Jan 26. 2018
8.90
Jan 30. 2018
9.43
2 Trading Days
5.93%
Link
LONG
Aug 24. 2018
5.00
Sep 6. 2018
5.26
8 Trading Days
5.25%
Link
LONG
Oct 17. 2019
4.93
Oct 30. 2019
5.20
9 Trading Days
5.45%
Link
LONG
Jan 3. 2020
5.50
Jan 24. 2020
6.68
14 Trading Days
21.40%
Link
LONG
Mar 19. 2020
4.37
Apr 1. 2020
4.99
9 Trading Days
14.09%
Link
LONG
Apr 8. 2020
5.23
Apr 21. 2020
5.70
8 Trading Days
8.93%
Link
LONG
Jun 15. 2020
7.14
Jul 2. 2020
8.00
13 Trading Days
11.92%
Link
LONG
Jan 11. 2021
1.46
Jan 28. 2021
1.81
12 Trading Days
23.82%
Link
LONG
Feb 1. 2021
2.23
Feb 17. 2021
2.92
11 Trading Days
30.96%
Link
LONG
May 25. 2021
1.78
Jun 2. 2021
1.88
5 Trading Days
5.48%
Link
Company Information
Stock Symbol
CRBP
Exchange
NasdaqGM
Company URL
http://www.corbuspharma.com
Company Phone
617-963-0103
CEO
Yuval Cohen
Headquarters
Massachusetts
Business Address
100 RIVER RIDGE DRIVE, NORWOOD, MA 02062
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001595097
About

Corbus Pharmaceuticals Holdings, Inc. engages in the development and commercialization of novel therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs. Its produc, JBT-101 is a novel synthetic oral endocannabinoid-mimetic drug that is intended to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. The company was founded in December 2013 and is headquartered in Norwood, MA.

Description

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Its lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases. The company is based in Norwood, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading